Critical Survey: Adlai Nortye (NASDAQ:ANL) & Immunovant (NASDAQ:IMVT)

Adlai Nortye (NASDAQ:ANL) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.

Earnings and Valuation

This table compares Adlai Nortye and Immunovant”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5.00 million	13.21	-$51.87 million	N/A	N/A
Immunovant	N/A	N/A	-$413.84 million	($2.85)	-5.29

Adlai Nortye has higher revenue and earnings than Immunovant.

Profitability

This table compares Adlai Nortye and Immunovant’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Immunovant	N/A	-80.99%	-72.23%

Institutional & Insider Ownership

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Adlai Nortye and Immunovant, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	0	1	0	0	2.00
Immunovant	0	3	8	1	2.83

Adlai Nortye presently has a consensus price target of $9.00, indicating a potential upside of 402.79%. Immunovant has a consensus price target of $35.20, indicating a potential upside of 133.58%. Given Adlai Nortye’s higher probable upside, equities analysts clearly believe Adlai Nortye is more favorable than Immunovant.

Risk and Volatility

Adlai Nortye has a beta of -0.94, indicating that its stock price is 194% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.

Summary

Immunovant beats Adlai Nortye on 6 of the 11 factors compared between the two stocks.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.